Basal cell carcinoma (BCC) · line 1 · Vismodegib monotherapy (locally advanced / metastatic BCC)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-VISMODEGIB-BCC`

ID	`IND-BCC-1L-VISMODEGIB`
Type	Indication
Status	reviewed 2026-05-04 \| pending_clinical_signoff
Diseases	`DIS-BCC`
Sources	`SRC-NCCN-SKIN-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Standard-track HHI for locally advanced/metastatic BCC. First-in-class; established safety/efficacy. Sonidegib is NCCN-listed alternative (aggressive track) for laBCC.

Used By

Algorithms

ALGO-BCC-1L - ALGO-BCC-1L